3AM Stock Chart & Stats
€31.60
-€0.40(-1.12%)
At close: 4:00 PM EDT
€31.60
-€0.40(-1.12%)
Day’s Range― - ―
52-Week Range€15.00 - €43.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.64B
Enterprise Value€2.66K
Total Cash (Recent Filing)€400.79M
Total Debt (Recent Filing)€979.41M
Price to Earnings (P/E)46.4
Beta0.40
Next Earnings
Nov 05, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.83
Shares Outstanding49,604,366
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)1.56
Price to Sales (P/S)0.38
P/FCF Ratio11.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.35Price Target Upside43.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.2
Revenue Forecast (FY)€3.42B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Scaling And Raised EBITDA OutlookRapid growth and a higher EBITDA outlook indicate expanding demand for Astrana’s value-based care platform. Continued reinvestment in payer and provider contracts could extend scale benefits and support durable operating growth.
Robust Cash Generation And DeleveragingStrong free cash flow conversion gives Astrana resources to reduce debt while funding growth initiatives. Lower leverage can improve financial resilience and leave the company better positioned to invest through changing reimbursement conditions.
Scaled Value-based Care Platform With Proven OutcomesConsistent shared-savings performance validates Astrana’s physician-led, technology-enabled model. Demonstrated ability to lower total care costs can strengthen payer and provider relationships, supporting contract wins and expansion in accountable care.
Bears Say
Material And Persistent Margin CompressionThe sharp multi-year decline in gross and net margins shows that revenue growth has not translated proportionally into profitability. If mix, medical costs, or risk performance remain unfavorable, earnings could stay vulnerable despite continued expansion.
Debt Remains Sizable Relative To Cash FlowDeleveraging is positive, but the remaining debt burden and thin cash-flow coverage limit financial flexibility. A slowdown in medical-cost performance or cash generation could constrain investment capacity and increase refinancing or liquidity risk.
Medicaid Attrition And Medical-cost PressureMembership losses can reduce the scale of managed populations, while elevated medical costs directly pressure risk-bearing economics. These issues may require contract rebalancing and operational remediation, creating ongoing uncertainty for margins and growth.
3AM FAQ
What was Astrana Health’s price range in the past 12 months?
Astrana Health lowest stock price was €15.00 and its highest was €43.40 in the past 12 months.
What is Astrana Health’s market cap?
Astrana Health’s market cap is €1.64B.
When is Astrana Health’s upcoming earnings report date?
Astrana Health’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Astrana Health’s earnings last quarter?
Astrana Health released its earnings results on Aug 06, 2026. The company reported €0.343 earnings per share for the quarter, beating the consensus estimate of €0.288 by €0.055.
Is Astrana Health overvalued?
According to Wall Street analysts Astrana Health’s price is currently Undervalued.
Does Astrana Health pay dividends?
Astrana Health does not currently pay dividends.
What is Astrana Health’s EPS estimate?
Astrana Health’s EPS estimate is 0.38.
How many shares outstanding does Astrana Health have?
Astrana Health has 49,604,366 shares outstanding.
What happened to Astrana Health’s price movement after its last earnings report?
Astrana Health reported an EPS of €0.343 in its last earnings report, beating expectations of €0.288. Following the earnings report the stock price went up 0.658%.
Which hedge fund is a major shareholder of Astrana Health?
Currently, no hedge funds are holding shares in DE:3AM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Astrana Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€45.35 (43.51% Upside)
€45.35 (43.51% Upside)
Blogger Sentiment
Bullish
DE:3AM Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
58.22%
Trailing 12-Months
Company Description
Astrana Health
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating with a physician-centered approach powered by advanced technology. Its operations are structured across three distinct divisions: Care Partners, Care Delivery, and Care Enablement. Astrana Health utilizes its exclusive platform for population health management and healthcare delivery to implement an integrated, value-based care model. This strategic approach empowers the healthcare providers within its network to offer high-quality care to their patients. The organization provides extensive care coordination services to a broad spectrum of stakeholders, including patients, their families, primary care physicians, specialists, acute care hospitals, other inpatient facilities, physician groups, and health plans. Its robust physician network encompasses primary care doctors, specialized practitioners, advanced practice providers (extenders), and hospital-based physicians. Astrana Health serves a diverse patient base, primarily those with insurance coverage—such as private plans, Medicare, Medicaid, and HMOs—but also extends care to uninsured individuals.
3AM Company Deck
3AM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial year-over-year top-line and profitability growth, improved operating leverage from AI-driven automation, meaningful cash generation and accelerated de-leveraging, successful integration of Prospect with expected synergies, and raised EBITDA guidance. Offsetting these positives are ongoing Medicaid membership attrition and program-specific headwinds in California, slightly elevated commercial cost trends, a minor one-time $15 million ACO REACH revenue reduction, and some uncertainty around exchange and Medicaid dynamics. On balance, the positive execution, scale gains, and trajectory of the AI-native operating system materially outweigh the near-term challenges and conservatively guided risks.View all DE:3AM earnings summaries3AM Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€45.35
▲(43.51% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Healthcare Services
―
Pediatrix Medical Group
―
―
US Physical Therapy
―
Aveanna Healthcare Holdings
―







